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Glycolate determination detects type I primary hyperoxaluria in dial-
ysis patients. The detection of type I primary hyperoxaluria is based on
the finding of exceedingly high oxalate excretion which is associated
with increased glycolate excretion. The differential diagnosis of this
disease may become a difficult task once end-stage renal disease
(ESRD) and anuria have supervened. The various procedures thus far
proposed to obviate this circumstance are complex, inaccurate or not
reproducible. In this paper we propose the accurate liquid chromato-
graphic determination of glycolate in blood and dialysate as a means to
detect type I primary hyperoxaluria in patients on maintenance hemo-
dialysis (RDT). The method is based on the enzymatic conversion of
glycolate to glyoxylate coupled with a-keto acid derivitization with
phenylhydrazine. The resulting phenyhydrazone is then resolved by
high-performance liquid chromatograph (HPLC). With this method,
plasma glycolate in 12 healthy controls was 7.8 1.7 jsmol/liter, almost
twentyfold less than previously reported. Five dialysis patients with
high serum oxalate, of whom four with primary hyperoxaluria and one
with Crohn's disease and presumed enteric oxalate hyperabsorption,
were checked by this method and compared to nine patients with
oxalosis-unrelated ESRD. The patients with hyperoxalemia were also
evaluated for their response to pyridoxine therapy. The measurement of
glycolate in blood drawn prior to and at the end of the dialysis session
as well as in the dialysate soundly discriminated the patients with type
I hyperoxaluria from all the other dialysis patients. Glycolate measure-
ment was shown to be much more powerful than oxalate in that patients
with oxalosis-induced ESRD exhibited an almost two hundred and
fiftyfold increase compared to the oxalosis-unrelated patients. There
was no overlapping at all irrespective of timing and type of sampling.
Glycolate measurement represented a valuable tool to distinguish
Crohn's disease related from genetically induced hyperoxalemia and to
assess responsiveness to pyridoxine treatment.
Primary hyperoxaluria is a rare inborn error of metabolism
involving oxalate by two distinct pathways: the more common
type I primary hyperoxaluria has now been recognized to be
due to deficiency of peroxisomal alanine:glyoxylate amino-
transferase which is located in the liver cells [1]; the more rare
type II is due to lack of D-glyceric dehydrogenase [2]. Both
types are featured by a marked increase in oxalate endogenous
production, which lead to progressive kidney destruction and to
systemic tissue deposition of oxalate. Detection of these syn-
dromes relies on the finding of persistent hyperoxaluria, with
urine oxalate usually exceeding 1 mmoll24 hours. High urine
oxalate is associated to increased excretion of both glycolate
and glyoxylate in type I hyperoxaluria, and to L-glycerate in
type II [2, 3]. Both types usually present with a very aggressive
recurrent calcium oxalate nephrolithiasis leading to end-stage
renal failure (ESRD). In these conditions detection and differ-
ential diagnosis by means of the usual ways, that is, their urine
determination, are not allowed. Various procedures have been
proposed to obviate this circumstance, including determination
of oxalate in plasma [4, 5], measurement of oxalate dynamics by
[14C]-oxalate dilution [61, detection of calcium oxalate crystal-
line deposits in body tissues [7, 8], and demonstration of
specific enzyme defects in liver tissue [1]. However, each of
these methods have some disadvantage: the determination of
oxalate in plasma requires complex sample manipulation to
prevent spontaneous oxalate generation [9, 10]; furthermore,
plasma oxalate raises not only in ESRD secondary to primary
hyperoxaluria but also in oxalosis-unrelated diseases [11, 12];
pyridoxine deficiency [13] and high-dose ascorbate supplements
[14] have been implicated as potential causes of hyperoxalemia
in dialyzed patients. Labelled oxalate dilution methods require
that radioactive material be handled. Studies of both crystalline
tissue deposits and liver biopsies are invasive and poorly
reproducible.
Since oxalate precursors can be expected to be retained in
renal failure, their detection in body fluids could represent a
useful approach to diagnosis. We have recently developed a
high-performance liquid chromatographic (HPLC) procedure
for the determination of glycolic acid in urine and plasma [15],
whose sensitivity permits detection of glycolate at normal range
levels. This procedure has been used for the measurement of
glycolate levels in blood and dialysate of uremic patients on
maintenance dialysis (RDT) for either oxalosis-induced or ox-
alosis-unrelated ESRD. It will be shown that glycolate deter-
mination can be a method of choice to identify type I primary
hyperoxaluria as well as to assess efficacy of pyridoxine therapy
in the course of RDT.
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Methods
Subjects studied
Four patients undergoing dialysis for hystologically-proven
systemic oxalosis were enrolled in this study.
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Patient B.M. was a 14-year-old boy who had been previously
referred to as featuring typical X-ray changes of kidney and
bone in the course of type I primary hyperoxaluria [16]. He had
passed his first stone when he was four years old and had had
several stone episodes until he was nine years old. At this time
he presented to our institution with bilateral nephrocalcinosis
associated to large-sized caliceal stones in both kidneys and
multiple stones along the right ureter. Serum creatinine was 123
pmoIIliter and creatinine clearance was 43 mllmin; urine oxalate
was 3,5 nimol/24 hours (oxalate/creatinine, 0.46 mmollmmol)
and urine glycolate was 2.56 mmol/24 hours (glycolate/creati-
nine, 0.33 mmoLlmmol). He was given pyridoxine (300 mg/day)
associated to high fluid intake and was sent to the referring
institution in Palermo. Renal function deteriorated progres-
sively and he had to be started on hemodialysis when he was 12.
The second study, to which these data refer, was performed 18
months later. He had discontinued pyridoxine after starting
RDT and this drug was not restored during this study period.
Patient M.A. was a 14-year-old girl who had been dialyzed for
21 months. The onset of the disease had occurred at the age of
six when she passed a renal stone. She was free of symptoms
until age 12 when she was admitted to Ospedali Riuniti in
Reggio Calabria with oliguria and uremia. X-ray films showed
that renal pelvis in both kidneys were entirely filled with large
radiopaque stones. Every attempt to remove urinary obstruc-
tion was unsuccessful and she was started on dialysis. Diagno-
sis of primary hyperoxaluria was based on renal biopsy depict-
ing the typical features of renal oxalosis and by the finding of
steep increases in plasma oxalate. Pyridoxine treatment (500
mg/day) was instituted and was being given when the present
study was performed in December 1989. Her clinical condition
progressively worsened during dialysis in that she developed
severe anemia and experienced thromboses of several arterio-
venous fistulas. Extensive calcifications of peripheral vessels
prevented the creation of a definitive vascular access. She died
in June 1990 of infectious complications due to subclavian
catheterization.
Patient B.F. was a 21-year-old man who had been on renal
replacement therapy for 72 months. Nephrolithiasis had begun
when he was four years old; at that time he had been operated
for bilateral pyelolithotomy. Bilateral renal stones recurred a
few months later, and since then he had severely recurrent
nephrolithiasis complicated by urinary tract infection, and
ultimately by chronic pyelonephritis. Diagnosis of type I hyper-
oxaluria was established by increased urine oxalate and glyco-
late. ESRD had supervened when he was 15 years old and he
had been treated with hemodialysis for few months until Sep-
tember 1984. At that time the patient underwent living-related
donor kidney transplantation; afterwards he was advised to
increase fluid intake and was given high dose pyridoxine (1200
to 1500 mg/day). Nonetheless renal function deteriorated pro-
gressively and he re-entered dialysis treatment in January 1986.
Renal biopsy of the grafted kidney exhibited extensive deposi-
tion of calcium oxalate crystals in renal tubules and intersti-
tium. In June 1986 he received a second cadaveric graft but he
had to be explanted after a few weeks due to acute graft
rejection. He was re-started on dialysis and was treated at the
Ospedali Riuniti, Reggio Calabria, where he was studied in
December 1989. He regularly took pyridoxine 300 mg/day
which was maintained during the first study. Oxalate and
glycolate measurements were carried out a second time 20 days
after stopping vitamin B6.
Patient S.F. was diagnosed as affected by primary oxalosis
after he had been on dialysis for five years, and has been
previously referred to as an example of primary oxalosis with
delayed onset and slow progression [17]. He had been healthy
until the age of 18, when he passed his first stone composed of
calcium oxalate. At the age of 28 he underwent surgery for large
stones in the left ureter and bladder. At that time serum
creatinine was 132 jmolJliter. Renal stones recurred thereafter
and he progressed to ESRD, so that he was started on RDT
when he was 33. During the subsequent five years on RDT his
major problems were severe anemia, increasing bone pain
unresponsive to vitamin D therapy and repeated thromboses of
the vascular access. He was finally referred to the Nephrology
Division of the University of Turin with a putative diagnosis of
secondary hyperparathyroidism, which was suspected by find-
ing subperiosteal reabsorption of the fingers and widespread
vascular calcifications. Since blood biochemistries were poorly
consistent with the diagnosis of hyperparathyroidism, bone
biopsy was performed and revealed extensive deposition of
calcium oxalate crystals filling medullary spaces. These findings
suggested primary hyperoxaluria as the underlying primary
disease. The patient was therefore enrolled in this study. First
measurements of blood and dialysate were carried out while he
was not taking pyridoxine. After diagnosis of type I primary
hyperoxaluna had been established he was given pyridoxine,
900 mg/day. The second study was performed 12 months later
while he was on pyridoxine.
Patient C.N. was a 32-year-old male undergoing dialysis for
18 months for renal and systemic amyloidosis secondary to
Crohn's disease; two years before entering dialysis he had been
operated on of extensive ileal resection. Since his plasma
oxalate was found to be steeply increased he was presumed to
represent a case of absorptive hyperoxalemia unrelated to
enzymatic defects. However, plasma levels of oxalate and
glycolate were poorly affected by changes in both dietary
oxalate and calcium supplements, so he was tested for pyridox-
me deficiency. Pyridoxine was given intravenously, 600 mg
three times a week at the end of dialysis, plus 300 mg orally in
the interdialytic days for 15 days, and he was restudied for
plasma oxalate and glycolate levels.
Nine patients (5 males and 4 females, aged 40.8 14.0 years)
who had been on RDT for 63 52 months were identified as
cases of oxalosis-unrelated renal failure. All the patients were
investigated while on their home diets and all were taking
vitamin D supplements and calcium carbonate at usual doses;
none was taking vitamin B6.
All these patients were being dialyzed by standard hemodi-
alysis or soft hemodiafiltration, with KT/V of urea, estimated
according to Sargent and Gotch single-pool-variable volume
model [181 of 1.1 through 1.4.
Twelve healthy subjects (7 males and 5 females, aged 41.0
14.4 years) were considered as controls.
Blood and dialysate sampling
Blood samples for glycolate, oxalate and creatinine determi-
nation were taken in the fasting state from the healthy subjects.
Samples from uremic patients were drawn by their arteriove-
nous fistula prior to and at the end of a dialysis session.
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Fig. 1. Reaction for glycolate HPLC assay. Glycolate oxidase (GAO)-catalyzed oxidation of glycolate to glyoxylate; the resulting glyoxylate
reacts with phenylhydrazine to produce the corresponding phenyihydrazone. The reaction is carried out at pH 8.3 and in the presence of cysteine
as a reducing substrate to eliminate hydrogen peroxide.
Predialysis blood samples were taken from the three hyperox-
alemic patients (namely patients B.F., S.F. and C.N.) who were
restudied on pyridoxine. All the samples were handled in such
a way as to prevent spontaneous generation of oxalate as
previously described [19]. Soon after being taken, blood was
placed on ice and processed without delay; blood was centri-
fuged at 1000 x g for 10 minutes at 4°C. One aliquot of whole
serum was used for creatinine determination. A total of 1.0 ml
aliquot of serum was acidified with 40 jxl of concentrated HCI,
vigorously vortex-mixed for six minutes and then ultrafiltered
without delay using YMT membranes (Amicon) with 30,000
Daltons molecular weight cut-off, and analyzed for oxalate as
soon as possible. One milliliter aliquot of serum for glycolate
determination was ultrafiltered in the same way as described
above, save that HC1 addition was omitted. Ultrafiltrates were
harvested and stored frozen at —20°C until analysis.
The whole dialysate from a single dialysis session was
collected on plastic bags to which 10 ml of concentrated HC1
had been added to prevent precipitation of calcium salts. Two 1
ml aliquots were stored frozen without further manipulation.
Samples of patients B.F. and M.A. were thoroughly proc-
essed by the laboratory of the referring Nephrology Division of
Reggio Calabria, and were sent to our laboratory immediately.
Chemical methods
Oxalate was determined by ion chromatography using a
Dionex QIC apparatus equipped with a conductimetric detector
as previously described [12].
Glycolate was determined by means of a HPLC procedure
derived by the original application in urine [15]. The method is
based on the enzymatic conversion of glycolate to glyoxylate
coupled with a-keto acid derivitization with phenylhydrazine;
the resulting phenylhydrazone is then resolved by the HPLC
procedure (Fig. 1). To eliminate any aspecific contribution to
the peak, a pre-incubation step was carried out at room tem-
perature for 120 minutes by mixing into 10 ml glass vials 25 p.1
of reconstituted (25 U in 1 ml phosphate buffer) glycolate
oxidase from spinach (glycolate:oxygen oxidoreductase, EC
1.1.3.15, Sigma Co., St Louis, Missouri, USA), 1.0 ml of 0.1
mollliter phosphate buffer and 50 p.1 of cysteine solution (439 mg
of L-cysteine hydrochloride in 25 ml of water). The derivatives
were prepared by adding 1.0 ml of pretreated phosphate buffer
with 50 p.1 of 500 mmollliter phenyihydrazine and 200 p.! of
standard, ultrafiltrate or dialysate samples. The blanks were
prepared accordingly by adding 1.0 ml of the above phosphate
buffer with phenylhydrazine. After vortexing, 25 p.1 of the
suspended glycolate oxidase were added and the solution was
vortexed again. The mixture was left at room temperature for 20
minutes, and the lightly yellow solution was thereafter injected
into the liquid chromatograph. Chromatography was performed
by a Varian 5500 LC, equipped with and UV variable wave-
length detector and a Rheodyne 7126 (Berkeley, California,
USA) automatic injection valve with a 50 p.1 loop. Peak eights
were measured with a Shimadzu R1A (Kyoto, Japan) recorder!
integrator. The detection was performed at 324 nm. An octade-
cylsylil 250 x 4 mm LiChrospher RP-18 10 p.m column (Merck)
was used throughout in connection with a 30 x 4 mm Perisorb
RP-18 30 to 40 p.m (Merck) guard column. In the described
conditions glycolate peak eluted in about 5.6 minutes. Figure 2
shows typical chromatograms of a standard solution, a blank
and plasma samples from a normal subject and a patient with
primary hyperoxaluria. The chromatographic signal includes
the glyoxylate concentration; however, when ten ultrafiltrates
from normal subjects were analyzed for glyoxylate by a modi-
fication of a method described previously [20], their contents
never exceeded 0.3 p.mol!liter. Glyoxylate was also determined
on all the predialysis ultrafiltrates from the patients with pri-
mary oxalosis yielding a mean of 23 14 p.mol/liter, so as to
contribute only 1.5% to the glycolate peak. These findings
prompted us to neglect glyoxylate contribution. The linearity of
the chromatographic response was good in the range 0 through
200 p.mollliter (the regression equation of the standard curve
being: y = 1.36 x — 1.45, r = 0.9987, P < 0.001; where Y
indicated peak eight as mm, and X glycolate concentration as
p.moliliter). The sensitivity was of 0.3 p.mollliter. Samples with
higher glycolate content were diluted before being analyzed.
The intra- and inter-run CV at 5.7 p.mollliter were 2.6 and
11.3%, respectively. Recoveries of added glycolate to plasma
ultrafiltrates averaged 98.9 6.8%. The efficiency of the ultrafil-
tration was tested by spiking plasma samples with glycolate prior
to ultrafiltration. Measured recoveries of 102 7%, corrected for
both volume reduction due to plasma proteins and Donnan effect,
suggested that complete ultrafiltration occurred. Recoveries
also tested on ultrafiltrates from uremic patients yielded com-
parable results. To test whether contaminants could interfere
with the glycolate assay, blood samples from both normal
subjects and hyperoxalemic patients were added with 0.5 mmol!
liter of oxaloacetate, a-ketoglutarate, glutarate, L-lactate, pyru-
Iii
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Table 1. Plasma levels of the considered parameters in normal
subjects and uremic patients
Normal
Subjects
Oxalosis-
unrelated
ESRD
Crohn's-related
hyperoxalemia
Type I
primary
oxalosis
Number 12 9 1 4
Creatinine 88 17.5 1017 l79 1275 816 l88
Oxalate 6.1 1.6 50.9 18.4a 119 162.0 24.0"
Glycolate 7.8 1.7 6.1 0.8 23.3 1536 1062"
Means SD are shown. Values for the patient with Crohn's disease
represent means of four replicated analyses performed off pyridoxine.
All data are expressed as mo1/liter.
a P < 0.00 1 vs. healthy subjects
b P < 0.001 vs. both healthy subjects and oxalosis-unrelated ESRD
vate, oxalate, mesoxalate, L-citrate, L-glucose, L-ascorbate,
L-tartrate, tartronate, malonate, maleate, malate, succinate as
well as main physiological L-amino acids, which did not pro-
duce any significant interference.
Serum creatinine was determined by routine method.
Results
Values from predialysis samples of uremic patients and from
fasting samples of normal subjects are- listed in Table 1. All the
uremic patients exhibited significant increases in plasma oxalate
levels as compared to normal subjects. Means from patients
with type I primary hyperoxaluria and from the one with enteric
hyperoxalemia were higher than that from oxalosis unrelated
patients. Plasma glycolate was enormously increased in the
case of primary oxalosis, whereas it was unchanged or only
mildly above control values in the other uremic patients.
Table 2 lists some dialysis related features in the uremic
patients. The striking changes of glycolate levels were con-
firmed in blood samples taken at different times of the dialysis
session as well as in dialysate collections. Interestingly, the
ratio of means between hyperoxaluric patients and oxalosis-
unrelated patients was about 3 for oxalate while it rose to over
Fig. 2. Typical HPLC chromatograms for the
analysis of plasma glycolate: glycolate 20
pmol/liter aqueous standard, 0.002
absorbance units full scale (A); aqueous
blank, 0.002 a.u.f.s. (B); sample from a
healthy control, 0.002 a.u.f.s. (C); predialysis
sample from a patient with type I
hyperoxaluria, 0.064 a.u.f.s. (D). The arrows
indicate the glyoxylate phenylhydrazone
peaks.
Table 2. Dial
E
ysis kinetics of oxalate and glycolate in patients with
SRD secondary to different renal diseases
Oxalosis- Type I
unrelated Crohn's-related primary
ESRD hyperoxalemia oxalosis
Predialysisa
Creatinine 1017 179 1275 816 188
Oxalate 50.9 18.4 119 162 24.0c
Glycolate 6.1 0.8 23.3 1536 l062C
Postdialysisa
Creatinine 383 151 433 342 149
Oxalate 20.5 11.8 35.9 60.4 l4.0c
Glycolate
Dialysate"
6.5 1.2 16.1 371 138C
Creatinine 17090 4760 23690 9910 901d
Oxalate 603 304 2379 1792 356C
Glycolate 347 77 798 11050 7333C
a Data are expressed as mo1Iliter
b Data are expressed as smo1es
C P < 0.001 and d P < 0.05 vs. patients with oxalosis unrelated ESRD
250 for glycolate. None of the measured samples overlapped
between the two groups of uremic people. Also, glycolate was
mildly increased in blood and dialysate of the patient with renal
amyloidosis; however, it remained far below the values ob-
served in primary hyperoxaluria. Glycolate measurement rep-
resented a valuable means to distinguish Crohn's disease re-
lated from genetically induced hyperoxalemia.
To evaluate the impact of pyridoxine therapy on plasma
levels of oxalate and glycolate, predialysis blood biochemistries
off pyridoxine were compared to those on pyridoxine. As listed
in Table 3 pyridoxine appeared to partially influence both
oxalate and glycolate levels in only one patient with type I
hyperoxaluria. We were unable to obtain measurements of
pyridoxine for patient M.A.; however, her chemistries on
pyndoxine suggested that she was not responsive to treatment.
None of the three patients with primary oxalosis who were
A B C D
0 10 20 0 10 20 0 10 20
Time, minutes
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Table 3. Effect of vitamin B6 administration on predialysis plasma
levels of oxalate and glycolatea
Off B6
Oxalate
0n B6b
Glyc
Off B6
olate
On B6
Type I primary
hyperoxaluria
B.M. 185 — 786 —
M.A. — 135 — 1441
B.F. 150 154 3066 2890
S.F. 180 94 980 685
Crohn's-related
hyperoxalemia
C.N. 119 55 23.3 4.6
a Data are expressed as /Lmol/literb Doses of pyridoxine: M.A., 500 mg/day; B.F., 300 mg/day; S.F.,
900 mg/day; C.N., 600 mg/day intravenously three times a week plus
300 mg orally in the interdialytic days.
assessed on had treatment plasma levels of glycolate less than
one hundredfold normal.
Conversely, plasma levels of glycolate in the patient with
Crohn's disease were restored to normal upon pyridoxine
substitution, which confirmed that vitamin B6 deficiency was
contributing to altered oxalate metabolism in this subset.
Discussion
Type I primary hyperoxaluria always results in chronic renal
failure due to the progressive destruction of renal tissue by
crystalline deposits of calcium oxalate. As a rule this syndrome
starts early in life and induces ESRD within the first two
decades of age [211. There were 221 patients recorded in the
EDTA Registry up to December 1986 with oxalosis as the
primary renal disease [221. The identification of the syndrome is
not difficult when patients are investigated before renal failure
induces anuria, in that oxalate excretion raises to over 1
mmoll24 hr [21, 23] and the measurement of corresponding
oxalate precursors in urine permits discrimination between the
various forms of hyperoxaluria [23]. Once ESRD and anuria
supervene, identification and differential diagnosis may become
a complicated task. This issue has been updated by the recent
recognition that a considerable heterogeneity exists in the
presentation of primary hyperoxaluria, with a slow course and
a delayed onset in some cases in which systemic oxalosis has
been reported to develop three to five years after the initiation
of RDT [24] or even after renal transplantation [25]. In these
instances diagnosis is also urged by prognostic considerations,
since the progressive development of systemic oxalosis, which
is not prevented by either dialysis treatment [6] or kidney
transplantation [7, 22], represents a serious threat to patient
survival.
It has been stressed earlier that the methods for the detection
and control of primary oxalosis in dialysis patients have many
drawbacks. Bone or liver biopsies permit a correct diagnosis,
but in addition to being invasive these techniques are poorly
reproducible. The determination of oxalate in plasma and
dialysate has been proposed as a means to detect primary
oxalosis [5], but methods for measuring oxalate in plasma are
not always available and their accuracy depends on delicate
sample handling [10, 19]. Moreover, plasma oxalate rises in
patients on dialysis for causes other than primary hyperox-
aluria, and some overlapping may have a confusing effect. This
has been pointed out in previous papers [11, 12] and is con-
firmed in the present study, which demonstrates that the
differences between the two groups of dialysis patients may be
cancelled out by different timing of the withdrawal. This mis-
leading event is partially obviated by the measurement of the
removed oxalate, but it requires that whole dialysate be col-
lected.
In this study, we have explored whether this problem could
be dealt with by means of the measurement of the main oxalate
precursor, glycolate, in blood and dialysate of patient on RDT.
Indeed, the determination of glycolate in serum and urines is
claimed as being a method of choice for the detection of
hyperoxaluria syndromes [23]; however, available data are not
recent and generally refer to patients studied prior to the onset
of anuric renal failure. We are not aware of any recent study of
the use of these measurements in ESRD or RDT, therefore this
investigation represents the first report on this issue. Our
results outline that the accurate determination of glycolate is a
valuable tool for the diagnostic approach to primary hyperox-
aluria. In fact, the method herein proposed enabled us to
observe extraordinarily high blood levels of glycolate in all the
patients with histologically proven oxalosis, and the results
were strongly corroborated by the dosage of glycolate in
dialysate. The differences were so striking that no overlap at all
was found between the two populations of dialysis patients
irrespective of time and type of sampling. The specificity of
glycolate increases for type I primary hyperoxaluria was also
proven by the results of the patient in which persistent hyper-
oxalemia was associated with Crohn's disease and ileal resec-
tion, since glycolate levels in blood and dialysate were different
in the two syndromes. Conversely, our method could even
detect a mild increase in glycolate levels, which successfully
revealed that pyridoxine deficiency was playing a subsidiary
role in this context.
Comparing basal glycolate levels to those measured on pyri-
doxine appeared to be a useful means of assessing if and how
patients responded to treatment. It has been previously re-
ported that pyridoxine can decrease oxalate generation in about
one third of the patients with the glycollic variant of primary
hyperoxaluria [26], and sequential studies of plasma oxalate as
well as of '4C-oxalate dynamics have been proposed to evaluate
pyridoxine efficacy [271. We suggest that accurate sequential
measurements of glycolate should similarly and perhaps more
simply meet this purpose. It is also reasonable to predict that
the changes of glycolate under pyridoxine substitution could be
more prompt and sensitive than those of oxalate. In fact plasma
(and dialysate) levels of the latter might be affected by a slow
equilibration with tissue deposits of oxalate, and this could
mask the Qngoing decrease of oxalate generation. The present
study was not originally intended to test this hypothesis, which
is worth being investigated prospectively.
In our laboratory glycolate determination has been shown to
represent a procedure much more powerful than so far sup-
posed on the basis of previous methods [28, 29]. In fact our
range for normal subjects are almost twentyfold lower than
those established by previous authors who used the same
enzymatic reaction of glycolate oxidase [28, 301. The specificity
of this reaction was significantly improved by the use of
phenylhydrazine—which reacts rapidly only with very acti-
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vated carbonyl moieties, that is, a-keto carboxylic groups—as a
derivatizing agent and by the use of the HPLC separation of the
corresponding phenyihydrazones. These steps efficiently pre-
vented overestimations arising from use of hydrogen peroxide
as a marker of the enzymatic reaction [15].
It remains to be explained why patients with oxalosis-unre-
lated ESRD had glycolate blood levels comparable to or mildly
lower than those of normal subjects, in the fact of the loss of
renal function. No definite conclusion can be put forward on the
basis of available data. However, we suggest that in this
context, that is, in the absence of any specific defect of its
pathway, glycolate may behave similarly to other intermediary
metabolites, such as lactate, pyruvate and acetoacetate. Blood
profiles of these organic anions have been shown to be influ-
enced by the acute changes in acid-base balance induced by
RDT. In fact their concentration is close to the normal range in
the predialysis samples and seem apparently unaffected by
dialysis, simply because their concentration at the end of the
session is the balance between metabolic generation and dialy-
sis removal [31]. This hypothesis is in keeping with most of our
findings for glycolate in patients with oxalosis-unrelated ESRD.
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